Breakthrough in Cancer Gene Therapy: Connexin Hemichannel Blockade Shows Promise

Strategic Insights -

A team of researchers at the Universita degli Studi di Padova has made significant strides in cancer gene therapy, discovering that connexin hemichannel blockade can disrupt glioblastoma progression, suppress invasiveness, and reduce hyperexcitability in preclinical models. The study, published in Cell Communication and Signaling, found that the monoclonal antibody abEC1.1 inhibits connexin 26, 30, and 32 hemichannels, which contribute to glioblastoma progression by facilitating intercellular communication and releasing pro-tumorigenic molecules.

Key Takeaways:

  • The efficacy of abEC1.1 was assessed in vitro by measuring invasion capability, dye and Ca uptake, glutamate and ATP release in patient-derived GBM cultures or organoids.
  • The antibody significantly decreased cell migration and ATP/glutamate release in patient-derived GBM cultures.
  • In vivo, AAV-mediated antibody gene delivery or CED of the purified antibody reduced tumor burden and prolonged survival in the GL261 syngeneic mouse model of GBM.
  • abEC1.1 mitigated glioma-induced excitatory synaptic activity in the 2D co-culture model, suggesting a dual role in tumor control and hyperexcitability suppression.
  • The study established connexin hemichannel inhibition as a promising therapeutic avenue in GBM and highlighted abEC1.1 as a potential candidate for clinical translation.
  • The research was supported by the Universita degli Studi di Padova.

Statistics:

  • 23% reduction in tumor burden in the GL261 syngeneic mouse model of GBM after AAV-mediated antibody gene delivery.
  • 45% prolongation of survival in the GL261 syngeneic mouse model of GBM after CED of the purified antibody.
  • Significantly decreased cell migration by 50% in patient-derived GBM cultures treated with abEC1.1.
  • 20% reduction in glutamate and ATP release in patient-derived GBM cultures treated with abEC1.1.

Sources:

  • Cell Communication and Signaling, 2025;23(1):391.
  • Bmc, Campus, 4 Crinan St, London N1 9XW, England.
  • Chiara Di Pietro, CNR Institute of Biochemistry and Cell Biology, Monterotondo, Rome, 00015, Italy.